YGION Biomedical GmbH is focused on developing individualized cancer immunotherapies, particularly through their innovative YGNITE™ technology platform. This platform integrates next-generation sequencing and bioinformatics to identify and produce neoepitope peptide vaccines that are specifically tailored to the unique tumor profiles of individual patients. By leveraging these advanced technologies, YGION aims to create "plug-and-play" cancer vaccines that can effectively activate the patient's immune system to target and eradicate tumor cells, thereby improving treatment outcomes and enhancing the quality of life for cancer patients.

The company is committed to advancing its research and development efforts, as evidenced by recent funding initiatives, including a €15 million Series A financing round and a significant grant from the Austrian Research Promotion Agency. These resources will support the preclinical development of YGION's lead program, YG1, and further enhance their neoantigen immunotherapy platform. Through these efforts, YGION Biomedical is positioning itself at the forefront of personalized cancer treatment, striving to redefine cancer care with therapies that are both safe and effective.

Austria

YGION Biomedical GmbH is an Austrian biotechnology company dedicated to developing individualized cancer immunotherapy. The company applies groundbreaking technology to create personalized neoantigen-based cancer vaccines, with a focus on maximizing effectiveness and minimizing side effects.

YGION Biomedical

Company Details